Global Biotherapeutics Cell Line Development Market to reach US$99.8 mn by 2022, Propelled by Rising Demand for Monoclonal Antibodies

As the biotherapeutics industry continues to grow exponentially, there has been an increase in the demand for mammalian cell line development. Big pharma companies have been aggressively pursuing the development of large molecule drugs by investing heavily in biotechnology. Moreover, with the increasing prevalence of diseases, there is an increase in the demand for biotherapeutics which consequently boosts the market for cell line development. According to the information by International Diabetes Federation (2014), the percentage of population suffering from diabetes across the globe would increase by 53% from 2014 to 2035.

Avail a Free Sample: http://bit.ly/1NEZM7X

The global biotherapeutics cell line development market is segmented by process, by cell line development option and by geography. The market by process segment has been sub-segmented as transfection and single cell cloning. The single cell cloning market is further segmented by method as manual limited dilution cloning, FACS, ClonePix and Others. The market by CLD option is segmented as In-house, outsource, hybrid and do-it-yourself. The ClonePix accounted for the largest market share of 37.4% in 2014.

Geographically, the market has been studied and estimated for five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the biotherapeutics cell line development market in 2014, followed by Europe. The largest market share of North America is attributed to growing demand due to increasing proportion of geriatric population and prevalence of diseases leading to increase in the demand of biotherapeutics and consequently cell line development. Asia Pacific was identified as the third largest market for biotherapeutics cell line development in 2014. The region is expected to register the fastest CAGR during the forecast period. Multinational biopharmaceutical manufacturers are making considerable investments in the region making it lucrative for the biotherapeutics cell line development.

Major players in this market are Becton Dickinson & Company (U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation, Japan), ProBioGen AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC. (U.S.), Sony Biotechnology Inc. (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

Browse Full Research Report: http://bit.ly/1mR3WCT

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.